Displaying 81 - 90 of 243
Alternative Name: Antiestrogen ICI 182780; Fulvestrant
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: No
Duration Type: Permanent
Delivery Method: Intrauterine
Developer: Femasys Inc
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium, APCOR R&M, Belgium
Development Stage: Regulatory
Development Phase: Limited Market Availability
Alternative Name: Fibroplant LNG14 (also LNG 20)
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Development Stage: Regulatory
Development Phase: Limited Market Availability
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Meril Life Science Private Ltd
Development Stage: Marketed
Development Phase: Limited Market Availability
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Prosan International B.V.
Development Stage: Marketed
Development Phase: Limited Market Availability
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Injectable
Developer: University of Washington, Focused Scientific
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal, Other
Development Stage: Compound ID/Selection
Development Phase: Discovery and Early Development
User: Female
Hormonal: Yes
Delivery Method: Injectable
Developer: University of Mumbai
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Sperm glycolytic enzyme
Target
Hormonal: No
Developer: University of North Carolina at Chapel Hill, NICHD
Development Stage: Target Validation
Development Phase: Discovery and Early Development

Pages

Displaying 51 - 60 of 70
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: Innolytics LLC
Development Stage: Lead Optimization
PC6
Alternative Name: Proprotein convertase 6
Target
Hormonal: No
Developer: CONRAD, Prince Henry's Institute of Medical Research, Australia
Development Stage: Target Validation
Alternative Name: Phosphodiesterase 3, 5, 9, PDE3A
Target
User: Female
Hormonal: No
Developer: Oregon Health & Science University, University of Minnesota
Development Stage: Target Identification
User: Female
Hormonal: No
Duration Type: Short-acting, Pericoital
Delivery Method: Vaginal Gel, Vaginal Ring
Developer: Ottawa Hospital Research Institute (OHRI)
Development Stage: Lead Optimization
User: Female
Hormonal: Yes
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Vindico NanoBio Technology Inc.
Development Stage: Lead Optimization
Alternative Name: PGE2
Target
User: Female
Hormonal: No
Developer: Oregon Health & Science University, Bayer HealthCare
Development Stage: Target Identification
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel, Other
Development Stage: Compound ID/Selection
Alternative Name: Retinoic acid receptor (RAR) antagonists
Target
User: Male
Hormonal: No
Duration Type: Short-acting
Developer: NICHD, Columbia University, University of Washington, University of Minnesota
Development Stage: Target Validation
Alternative Name: l-CDB-4022
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Development Stage: Lead Optimization
Alternative Name: Serum- and Glucocorticoid-Regulated Kinase
Target
User: Female
Hormonal: No
Developer: CONRAD, Imperial College, London
Development Stage: Target Identification

Pages

Displaying 21 - 30 of 121
Alternative Name: DVD2
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal, Other
Developer: FHI 360
Development Stage: Phase I
Alternative Name: DMAU
User: Male
Hormonal: Yes
Duration Type: Short-acting
Developer: BIOQUAL, Inc., NICHD, University of California at Los Angeles
Development Stage: Phase I
Alternative Name: Depot Medroxyprogesterone Acetate (DMPA) + Testosterone
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable, Subdermal
Developer: ANZAC Research Institute
Development Stage: Phase I
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: National Research Institute for Family Planning in Beijing
Alternative Name: Dapivirine (DPV) + levonorgestrel (LNG) vaginal ring
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: International Partnership for Microbicides, USAID
Development Stage: Phase I
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier, Vaginal Gel
Developer: ReProtect Inc.
Development Stage: Phase II
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Bayer HealthCare
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Emergency
Delivery Method: Vaginal Gel, Vaginal, Other
Developer: Viramal Limited
Development Stage: Pre-clinical
Alternative Name: Merck Vaginal Ring MK-8342B
User: Female
Hormonal: Yes
Delivery Method: Vaginal Ring
Developer: Merck
Development Stage: Phase III
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: GeSea Biosciences, FHI 360, pH Sciences
Development Stage: Pre-clinical

Pages

Displaying 11 - 20 of 52
User: Female
Hormonal: Yes
Duration Type: Emergency
Delivery Method: Oral
Developer: HRA Pharma
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Pregna International Limited
Development Stage: Marketed
Alternative Name: ENG + EE Vaginal Ring
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Amneal
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: HLL Lifecare Limited, Sree Chitra Tirunal Institute for Medical Sciences & Technology (SCTIMST)
Development Stage: Marketed
Alternative Name: Gold T IUD; Novaplus T 380 Ag IUD; Novaplus T 380 Cu IUD; Ancora 375 Ag IUD; Ancora 375 Cu IUD; Ancora 250 Cu Mini IUD
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Eurogine
Development Stage: Marketed
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Famy Care Ltd.
Development Stage: Marketed
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium, APCOR R&M, Belgium
Development Stage: Regulatory
Alternative Name: Fibroplant LNG14 (also LNG 20)
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Development Stage: Regulatory
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Meril Life Science Private Ltd
Development Stage: Marketed
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Prosan International B.V.
Development Stage: Marketed

Pages

CSV